FORA Capital LLC Makes New Investment in Vaxcyte, Inc. (NASDAQ:PCVX)

FORA Capital LLC bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 34,379 shares of the company’s stock, valued at approximately $3,928,000.

Other institutional investors also recently made changes to their positions in the company. RA Capital Management L.P. grew its position in shares of Vaxcyte by 4.0% during the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock worth $560,398,000 after acquiring an additional 312,500 shares during the last quarter. Driehaus Capital Management LLC boosted its stake in Vaxcyte by 3.6% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,934,747 shares of the company’s stock valued at $146,093,000 after purchasing an additional 66,940 shares during the period. Charles Schwab Investment Management Inc. grew its position in Vaxcyte by 47.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock worth $148,075,000 after purchasing an additional 419,600 shares during the last quarter. Novo Holdings A S increased its stake in shares of Vaxcyte by 12.4% in the second quarter. Novo Holdings A S now owns 950,000 shares of the company’s stock valued at $71,734,000 after purchasing an additional 105,000 shares during the period. Finally, Maverick Capital Ltd. raised its holdings in shares of Vaxcyte by 93.7% during the second quarter. Maverick Capital Ltd. now owns 687,908 shares of the company’s stock valued at $51,944,000 after buying an additional 332,777 shares during the last quarter. 96.78% of the stock is owned by institutional investors.

Insider Activity

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $106.80, for a total value of $854,400.00. Following the completion of the transaction, the chief operating officer now directly owns 205,695 shares in the company, valued at $21,968,226. This trade represents a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Grant Pickering sold 2,366 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total transaction of $245,803.74. Following the sale, the chief executive officer now owns 137,398 shares in the company, valued at $14,274,278.22. This represents a 1.69 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 102,464 shares of company stock worth $11,455,576. Insiders own 3.10% of the company’s stock.

Vaxcyte Price Performance

Vaxcyte stock traded down $0.26 during midday trading on Wednesday, hitting $91.19. The company’s stock had a trading volume of 29,356 shares, compared to its average volume of 903,724. Vaxcyte, Inc. has a 12 month low of $48.81 and a 12 month high of $121.06. The stock’s 50-day moving average price is $106.93 and its 200-day moving average price is $89.94.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the company earned ($0.91) earnings per share. As a group, sell-side analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Mizuho increased their price objective on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Bank of America lifted their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Leerink Partners increased their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group boosted their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.